Too many scientific breakthroughs are left on the laboratory bench instead of being translated into next-generation cancer treatments. This is largely due to the lack of seed funding for early-stage oncology startups, the so-called “Valley of Death” during which investment is too risky for traditional VCs and pharmaceutical companies.

AIM-HI Accelerator Fund bridges the gap from bench to bedside by providing the funding that others won’t. Moreover, we have inspired a broad network of co-investors who believe in our programs and invest in these early-stage oncology companies.

Our non-profit is the first of its kind to bring new therapies and diagnostic tools to patients, all while generating sustainable revenues for future cancer research.